771 related articles for article (PubMed ID: 31371939)
1. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
2. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
4. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
5. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
6. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
9. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
10. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
11. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
12. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.
Zayed Y; Barbarawi M; Kheiri B; Haykal T; Chahine A; Rashdan L; Hamid K; Sundus S; Banifadel M; Aburahma A; Bachuwa G; Chandran A
Clin Respir J; 2019 Jul; 13(7):413-428. PubMed ID: 30947394
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
Tariq SM; Thomas EC
Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
[TBL] [Abstract][Full Text] [Related]
16. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
17. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW; Kim HJ; Jang EJ; Lee CH
Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
[TBL] [Abstract][Full Text] [Related]
20. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
Long H; Xu H; Janssens JP; Guo Y
Respir Res; 2021 Jul; 22(1):209. PubMed ID: 34301267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
